survival analysis of of cdk4/6 inhibitors andendocrine therapy in hr positive,her2 negative day1
Published 3 years ago • 81 plays • Length 17:31Download video MP4
Download video MP3
Similar videos
-
34:58
management of hr-positive/her2-negative early breast cancer: taking direction from the updated gu...
-
2:19
cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
7:15
asco 2023 expert report in hr positive, her2 negative breast cancer by catherine harper-wynne
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
5:16
cdk4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in hr-positive/her2-nega...
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
8:39
final overall survival analysis of monarch 1
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
1:22
dr. rugo on resistance to cdk4/6 inhibitors in hr breast cancer
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference
-
0:57
evaluating the benefits of selective cdk4 inhibition in hr /her2- breast cancer
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
1:13
overall survival data of the monarch-2 trial in hr /her2- breast cancer
-
1:26
ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
-
1:18
dr. yardley on the utility of cdk4/6 inhibitors in metastatic hr breast cancer